Menopause Hormone Therapy and Dementia Risk: What the Latest Evidence Really Shows

Introduction

Menopause hormone therapy, often called MHT or hormone replacement therapy, has long been prescribed to relieve menopausal symptoms such as hot flashes, sleep disruption, and mood changes. Over the past two decades, another question has fueled public and clinical debate: does menopause hormone therapy affect the risk of dementia or cognitive decline later in life?

Women account for nearly two thirds of people living with dementia worldwide. This imbalance has led researchers to explore whether hormonal changes during menopause contribute to long term brain health. Some early studies suggested that estrogen therapy might protect memory, while later trials raised concerns about possible harm.

In December 2025, a large and comprehensive systematic review and meta analysis published in The Lancet Healthy Longevity examined this issue in depth. The findings provide important clarity for patients, clinicians, and policymakers.

This article explains what the study found, why earlier evidence was conflicting, and what the results mean for women considering or already using menopause hormone therapy.

Why Menopause Hormone Therapy Was Linked to Dementia Risk

During menopause, levels of estrogen and progesterone decline sharply. These hormones play roles not only in reproductive health but also in brain function, including memory, sleep, and mood regulation.

Because estrogen interacts with brain regions involved in learning and cognition, researchers hypothesized that hormone therapy might reduce the risk of dementia if started around the time of menopause. This idea became known as the “critical window” or “timing hypothesis.”

However, the evidence has never been consistent. Observational studies often suggested benefits, while randomized controlled trials showed neutral or negative results. Understanding the difference between these study types is essential.

Overview of the Lancet Healthy Longevity Review

The 2025 Lancet review is one of the most rigorous evaluations to date on this topic.

Study scope and design

Researchers reviewed and analyzed:

• One randomized controlled trial
• Nine high quality observational studies
• Over one million postmenopausal women
• Follow up periods ranging from several years to nearly two decades

The analysis focused on whether menopause hormone therapy affected the risk of:

• All cause dementia
• Alzheimer’s disease
• Mild cognitive impairment

The review also examined whether risk differed based on:

• Type of hormone therapy, estrogen only versus combined estrogen and progestogen
• Duration of use
• Age at initiation

Key Finding: No Clear Effect on Dementia Risk

The most important conclusion is straightforward.

Menopause hormone therapy neither clearly increases nor decreases the risk of dementia.

Across all high quality studies, there was no strong or consistent evidence that hormone therapy protects against dementia. At the same time, the overall findings did not show a large or definitive increase in risk either.

This reinforces current clinical guidance that menopause hormone therapy should not be prescribed for dementia prevention.

What the Study Found About Different Types of Hormone Therapy

Estrogen only therapy

Estrogen only therapy is typically prescribed to women who have had a hysterectomy.

• Randomized trial data showed a possible increase in dementia risk when estrogen therapy was started after age 65, but results were imprecise
• Observational studies showed mixed findings, with some suggesting slight benefit and others showing no effect

Overall, the certainty of evidence for estrogen only therapy was rated as low to very low.

Combined estrogen and progestogen therapy

Combined therapy is the most common form of MHT because most women retain their uterus.

• One large randomized trial showed a small increase in dementia risk when therapy was initiated after age 65
• Observational studies again produced inconsistent results

The absolute difference in dementia cases was small, and the certainty of evidence ranged from moderate to very low depending on study design.

Does Timing of Hormone Therapy Matter?

A major question has been whether starting hormone therapy earlier, closer to menopause, could protect the brain.

The Lancet review specifically examined this possibility.

• Women who started MHT between ages 45 and 55 did not show a reduced risk of dementia
• Starting therapy after age 60 did not consistently increase or decrease risk either
• No clear “protective window” was identified

These findings challenge the idea that early hormone therapy offers long term cognitive protection.

Duration of Hormone Therapy and Dementia Risk

Another theory suggested that long term hormone use might influence dementia risk differently than short term use.

The review analyzed short, medium, and long duration therapy:

• Less than 5 years of use showed no consistent benefit or harm
• Use between 5 and 10 years showed uncertain results
• Use longer than 10 years showed mixed findings with very low certainty

In practical terms, the data do not support extending hormone therapy for the purpose of brain protection.

Why Earlier Studies Were Conflicting

Much of the confusion around hormone therapy and dementia comes from differences in study design.

Observational studies

These studies follow people who choose to use hormone therapy and compare them to those who do not.

Problems include:

• Healthy user bias, where hormone users are often healthier and wealthier
• Incomplete data on adherence
• Reliance on medical records rather than confirmed diagnoses

These limitations can exaggerate benefits.

Randomized controlled trials

RCTs randomly assign participants to receive hormone therapy or placebo.

They provide stronger evidence but often:

• Enrolled women aged 65 or older, which is not typical clinical practice
• Were stopped early due to non cognitive risks
• Had high dropout rates

The Lancet review carefully weighed both types of evidence and rated certainty using the GRADE framework.

What About Women With Early Menopause or Premature Ovarian Insufficiency?

One of the most important gaps identified in the review concerns women who experience menopause early or prematurely.

The researchers found:

• No high quality studies examining dementia risk in this group
• No evidence supporting hormone therapy for dementia prevention in early menopause
• No data on testosterone therapy and cognitive outcomes

Despite some guidelines recommending hormone therapy for other health reasons in premature ovarian insufficiency, dementia prevention is not supported by current evidence.

What This Means for Clinical Practice

The findings align closely with existing guidance from:

• The UK National Institute for Health and Care Excellence
• The US Preventive Services Task Force
• The Lancet Commission on Dementia Prevention

Key takeaways for patients and clinicians:

• Hormone therapy should be prescribed for symptom relief, not dementia prevention
• Decisions should be individualized based on menopausal symptoms, cardiovascular risk, cancer risk, and patient preferences
• Cognitive benefits should not be expected from hormone therapy

Future Research Directions

The authors emphasize the need for better research, particularly:

• Long term studies starting hormone therapy during midlife
• Clear differentiation between hormone formulations and delivery methods
• Inclusion of women with mild cognitive impairment
• Studies examining genetic risk factors such as APOE status
• Research on testosterone and alternative therapies

Until such data are available, caution and evidence based prescribing remain essential.

Final Thoughts

Menopause hormone therapy remains an effective treatment for menopausal symptoms and can significantly improve quality of life for many women. However, based on the most comprehensive evidence available, it should not be used with the expectation of preventing dementia.

For women concerned about cognitive health, strategies with stronger evidence include cardiovascular risk reduction, physical activity, cognitive engagement, hearing loss management, and education.

As research evolves, guidance may change. For now, the message is clear: hormone therapy decisions should focus on present day benefits and risks, not unproven long term brain protection.

Sources

• Melville M et al. Menopause hormone therapy and risk of mild cognitive impairment or dementia. The Lancet Healthy Longevity, 2025
• Livingston G et al. The Lancet Commission on Dementia Prevention. The Lancet, 2024
• UK National Institute for Health and Care Excellence. Menopause: identification and management, 2024
• Shumaker SA et al. Women’s Health Initiative Memory Study. JAMA, 2003 and 2004
• Vinogradova Y et al. Menopausal hormone therapy and dementia risk. BMJ, 2021

Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice. Menopause hormone therapy decisions should always be made in consultation with a qualified healthcare professional who can assess individual risks, benefits, and medical history. Never start, stop, or change hormone therapy based solely on information found online.